Evidence map›Paper›PMID 41066509›Full record

ArticleJournal of cellular and molecular medicine2025

The Janus Face of SPAG6: Inducing EMT in Luminal Breast Cancer Cells Amidst Widespread Expression Loss in Breast Tumours.

Antonio Sechi, Jolein Mijnes, Sophia Villwock, Michael Rose, Florian Steib, Sarah Bringezu, Jonas Berger, Carmen Schalla, Sonja von Serenyi, Jana Dietrich and 15 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01049425 (Randomised Comparison of Adjuvant Docetaxel / Cyclophosphamide With Sequential Adjuvant EC / Docetaxel Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01049425 phase3completednot on this map

Randomised Comparison of Adjuvant Docetaxel / Cyclophosphamide With Sequential Adjuvant EC / Docetaxel Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer

TypeinterventionalSponsorWomen's Cancer Study Group GmbHRan2009 to 2018Enrolled3,198ConditionsPrimary Breast Cancer, Her2 Non-overexpressingArmsEpirubicin, Cyclophosphamide, Docetaxel
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Antonio SechiDepartment of Cell and Tumor Biology, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Jolein MijnesInstitute of Pathology, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Sophia VillwockInstitute of Pathology, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Michael RoseInstitute of Pathology, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Florian SteibInstitute of Pathology, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Sarah BringezuInstitute of Pathology, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Jonas BergerInstitute of Pathology, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Carmen SchallaDepartment of Cell and Tumor Biology, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Sonja von SerenyiInstitute of Pathology, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Jana DietrichInstitute of Pathology, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Nadina Ortiz-BrüchleInstitute of Pathology, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Lara HeijInstitute of Pathology, University Hospital of Essen, Essen, Germany.
Jan BednarschDepartment of Surgery and Transplantation, University Hospital Essen, Essen, Germany.
Oleg GluzBreast Center Niederrhein, Evangelical Hospital Bethesda, Moenchengladbach, Germany.
Ulrike NitzBreast Center Niederrhein, Evangelical Hospital Bethesda, Moenchengladbach, Germany.
Nadia HarbeckWest German Study Group, Moenchengladbach, Germany.
Monika GraeserBreast Center Niederrhein, Evangelical Hospital Bethesda, Moenchengladbach, Germany.
Christine Zu EulenburgWest German Study Group, Moenchengladbach, Germany.
Mohammad Parsa MohammadianInstitute of Biostatistics and Registry Research, Brandenburg Medical School Theodor Fontane, Neuruppin, Germany.
Katarzyna JóźwiakInstitute of Biostatistics and Registry Research, Brandenburg Medical School Theodor Fontane, Neuruppin, Germany.
Hans-Heinrich KreipeInstitute of Pathology, Medical School Hannover, Hannover, Germany.
Matthias ChristgenInstitute of Pathology, Medical School Hannover, Hannover, Germany.
Martin RadnerInstitute of Pathology, Medical School Hannover, Hannover, Germany.
Danny JonigkInstitute of Pathology, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Edgar DahlInstitute of Pathology, Medical Faculty, RWTH Aachen University, Aachen, Germany.ORCID 0000-0002-8439-7994

Funding

Deutsche Forschungsgemeinschaft (DFG) 331065168RWTH Aachen University
6 · The paper itself

Abstract

Understanding the role and molecular regulation of genes associated with tumour cell motility may be informative for future cancer therapy development. Sperm-associated antigen 6 (SPAG6) gene, encoding an evolutionarily highly conserved flagellar motility protein, is regulated by promoter hypermethylation in breast cancer. Our in silico analysis of healthy and breast cancer tissues from The Cancer Genome Atlas (TCGA) showed tumour-specific SPAG6 promoter hypermethylation in all molecular subtypes. Immunohistochemistry on the independent WSG PlanB breast cancer cohort (n = 2241) confirmed comprehensive down-regulation of SPAG6 on the protein level. In vitro models demonstrated that SPAG6 overexpression in luminal cells exhibited strongly increased migration capacity (p < 0.0001) and characteristics of epithelial-mesenchymal transition (EMT) with actin and E-cadherin displacement. We propose that SPAG6 may have an important role in triggering the EMT program in luminal breast cancer cells, driving tumour progression and metastasis. Trial Registration: ClinicalTrials.gov identifier: NCT01049425.

Indexed as

Breast NeoplasmsEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticCadherinsCell Line, TumorCell MovementClinical Trials, Phase III as TopicDNA MethylationFemaleHumansPromoter Regions, GeneticRandomized Controlled Trials as TopicCadherinsbreast cancercell migrationEMTluminal ASPAG6

Identifiers

PMID41066509
PMCPMC12510430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.